NOMÉGESTROL (ACÉTATE DE)

EUEMA:by INN G03DB04(WHO) In general: ℞ (Prescription only) [(8S,9S,10R,13S,14S,17R)-17-acetyl-6,13-dimethyl-3-oxo-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate 58652-20-3 91668 DB13981 82771 83J78V5W05 D08281 CHEBI:135564 ChEMBL1476022 DTXSID90207349 Interactive image CC1=CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4C1=CC(=O)CC4 InChI=1S/C23H30O4/c1-13-11-20-18(17-6-5-16(26)12-19(13)17)7-9-22(4)21(20)8-10-23(22,14(2)24)27-15(3)25/h11-12,17-18,20-21H,5-10H2,1-4H3/t17-,18-,20-,21+,22+,23+/m1/s1Key:IIVBFTNIGYRNQY-YQLZSBIMSA-N Nomegestrol acetate(NOMAC), sold under the brand namesLutenylandZoelyamong others, is aprogestinmedication which is used inbirth control pills,menopausal hormone therapy, and for the treatment ofgynecological disorders.It is available both alone and in combination with anestrogen.NOMAC is takenby mouth.Abirth control implantfor placementunder the skinwas also developed but ultimately was not marketed. Side effectsof NOMAC includemenstrual irregularities,headaches,nausea,breast tenderness, and others.NOMAC is a progestin, or asyntheticprogestogen, and hence is anagonistof theprogesterone receptor, thebiological targetof progestogens likeprogesterone.It has someantiandrogenicactivity and no other importanthormonalactivity. Nomegestrol, a related compound, was patented in 1975, and NOMAC was described in 1983.NOMAC was first introduced for medical use, for the treatment of gynecological disorders and in menopausal hormone therapy, inEuropein 1986.It was subsequently approved in Europe in 2011 as a component of birth control pills.NOMAC is available widely throughout the world.It is not available in theUnited StatesorCanada.